MXPA04004364A - Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica. - Google Patents

Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Info

Publication number
MXPA04004364A
MXPA04004364A MXPA04004364A MXPA04004364A MXPA04004364A MX PA04004364 A MXPA04004364 A MX PA04004364A MX PA04004364 A MXPA04004364 A MX PA04004364A MX PA04004364 A MXPA04004364 A MX PA04004364A MX PA04004364 A MXPA04004364 A MX PA04004364A
Authority
MX
Mexico
Prior art keywords
treatment
fsd
pmsa
sexual dysfunction
female sexual
Prior art date
Application number
MXPA04004364A
Other languages
English (en)
Inventor
Ebrahim Versi
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04004364A publication Critical patent/MXPA04004364A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un conjunto de formas de dosis farmaceuticas, cada una comprende por lo menos dos agentes terapeuticos seleccionados de (a) un estrogeno (b) un androgeno, y (c) un antimuscarinico, en cantidades de dosis totales relativas que son terapeuticamente efectivas en el tratamiento de la disfuncion sexual femenina (FSD) o la abstinencia sexual posterior a la menopausia (PMSA), dichas forma de dosis se adaptan para la administracion intravaginal; un metodo para el tratamiento del FSD o PMSA comprende administrar en forma intravaginal, en un regimen de tratamiento que se extiende durante un periodo de por los menos 7 dias, formas de dosis, por lo menos una porcion de las cuales comprende do o mas agentes terapeuticos seleccionados de (a) un estrogeno, (b) un androgeno y (c) un antimuscarinico, en cantidades de dosis totales y relativas que son terapeuticamente efectivas en el tratamiento del FSD o PMSA, en donde no se administra mas de una forma de dosis al dia; tambien se proporciona un equipo que es util en la implementacion de dicho regimen de tratamiento.
MXPA04004364A 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica. MXPA04004364A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34450701P 2001-11-09 2001-11-09
PCT/US2002/036167 WO2003039553A1 (en) 2001-11-09 2002-11-12 Compositions for treatment of postmenopausal female sexual dysfunction

Publications (1)

Publication Number Publication Date
MXPA04004364A true MXPA04004364A (es) 2004-08-11

Family

ID=23350815

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04003866A MXPA04003866A (es) 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
MXPA04004364A MXPA04004364A (es) 2001-11-09 2002-11-12 Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA04003866A MXPA04003866A (es) 2001-11-09 2002-11-07 Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.

Country Status (6)

Country Link
US (2) US20030118633A1 (es)
EP (2) EP1441707A1 (es)
JP (2) JP2005512995A (es)
CA (2) CA2466336A1 (es)
MX (2) MXPA04003866A (es)
WO (2) WO2003039524A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002366800B2 (en) 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
WO2004043429A1 (en) * 2002-11-12 2004-05-27 Pharmacia & Upjohn Company Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, and at least one agent selected from an estrogen and an anti-muscarinic
AU2004203700B2 (en) 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP2400300A1 (en) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
JP5756588B2 (ja) 2005-07-15 2015-07-29 ミセル テクノロジーズ、インコーポレイテッド 制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
KR101505884B1 (ko) 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2111184B1 (en) 2007-01-08 2018-07-25 Micell Technologies, Inc. Stents having biodegradable layers
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
JP2010527746A (ja) 2007-05-25 2010-08-19 ミセル テクノロジーズ、インコーポレイテッド メディカルデバイスコーティング用ポリマーフィルム
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
CN102089262A (zh) * 2008-04-09 2011-06-08 康瑟特制药公司 3-(2-羟基-5-甲基苯基)-n，n-二异丙基-3-苯丙胺的衍生物及其使用方法
MX2010011485A (es) 2008-04-17 2011-03-01 Micell Technologies Inc Stents que contienen capas bioadsorbibles.
GR1006406B (el) * 2008-05-06 2009-05-26 Specifar Abee ���������� ������� ��� ������������� ��������� Μικροδισκια παρατεταμενης αποδεσμευσης της τρυγικης τολτεροδινης
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
AU2009270849B2 (en) 2008-07-17 2013-11-21 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2756386C (en) 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2687215B1 (en) * 2012-07-18 2018-11-28 Georges Debled Mesterolone pharmaceutical composition for dihydrotestosterone deficiencies in woman
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
AU2014349132A1 (en) * 2013-10-22 2016-04-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life
WO2023039500A1 (en) * 2021-09-10 2023-03-16 Statera Pharma Inc. Local delivery of growth and repair promoting compounds for treating, reducing and/or preventing stress urinary incontinence and fecal incontinence

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US262115A (en) * 1882-08-01 Moeeis pollak
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
US6770295B1 (en) * 1998-08-27 2004-08-03 Pharmacia Ab Therapeutic formulation for administering tolterodine with controlled release
MXPA01012769A (es) * 1999-06-11 2003-06-24 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales para mujeres.
DOP2002000364A (es) * 2001-03-28 2002-10-15 Pfizer Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad

Also Published As

Publication number Publication date
US20030130244A1 (en) 2003-07-10
US20030118633A1 (en) 2003-06-26
MXPA04003866A (es) 2004-07-08
CA2464707A1 (en) 2003-05-09
JP2005514345A (ja) 2005-05-19
WO2003039553A1 (en) 2003-05-15
CA2466336A1 (en) 2003-05-15
EP1443939A1 (en) 2004-08-11
WO2003039524A1 (en) 2003-05-15
WO2003039553B1 (en) 2004-07-08
JP2005512995A (ja) 2005-05-12
EP1441707A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
MXPA04004364A (es) Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.
NZ514574A (en) Novel method of treatment
HU0101543D0 (en) Compositions and methods for treating femal sexual dysfunction
BG104620A (en) Oral pharmaceutical extended release dosage form
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IL106253A0 (en) Controlled release oral solid pharmaceutical dosage form and its preparation
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
NO982902L (no) FremgangsmÕte og preparatsett for Õ hindre befruktning hos hunn-pattedyr som omfatter en kombinasjon av gestagen og °strogen
MXPA03005741A (es) Metodos y formulaciones para el tratamiento de disfuncion sexual femenina.
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
GB9727131D0 (en) Therapeutic agents
PL343609A1 (en) Method for the treatment of fertility disorders
YU56702A (sh) Korišćenje fsh za lečenje neplodnosti
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
WO2001021194A3 (en) Method for the therapeutic management of endometriosis and fallopian tube obstruction
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
DK0692963T3 (da) Anvendelse af terbinafin til terapeutisk behandling af pneumocystose
CA2403674A1 (en) The use of t3 for treating congestive heart failure
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten
HUP0203655A2 (hu) Telítetlen 14,15-ciklopropano-androsztánok, előállításukat szolgáló eljárás és ezen vegyületeket tartalmazó gyógyszerészeti készítmények
MD2068G2 (ro) Metodă de tratament al infecţiei cu Herpes simplex
UA79424C2 (en) Use of fsh for treatment of infertility in women